Crossmark

Oxindole–benzothiazole hybrids as CDK2 inhibitors and anticancer agents: design, synthesis and biological evaluation

Published Online: 2024-09-13

Authors

Abdel-Mohsen, Heba T.
Funding

Funding for this research was provided by:

National Research Centre Egypt
License Information

Text and Data Mining valid from 2024-09-13

Version of Record valid from 2024-09-13
More Information

Article History

Received: 7 April 2024

Accepted: 21 August 2024

First Online: 13 September 2024

Declarations

:

: Egyptian National Research Centre Medical Research Ethics Committee (Approval number 13445062023). Consent to participate is not applicable.

: Not applicable.

: The authors declare no competing interests.

Document is current